Oncimmune (LON:ONC) Reaches New 12-Month Low – Should You Sell?

Oncimmune Holdings plc (LON:ONC) hit a new 52-week low on Wednesday . The company traded as low as GBX 3.86 ($0.05) and last traded at GBX 3.86 ($0.05), with a volume of 541160 shares changing hands. The stock had previously closed at GBX 4 ($0.05).

Oncimmune Stock Performance

The company has a 50-day moving average of GBX 12.49 and a 200-day moving average of GBX 14.65. The firm has a market capitalization of £4.37 million, a price-to-earnings ratio of 0.44 and a beta of 1.19. The company has a current ratio of 1.14, a quick ratio of 0.63 and a debt-to-equity ratio of -412.06.

Oncimmune (LON:ONC) last announced its quarterly earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.